Gibbel (688566): Sales reforms continue to promote rapid release of core products
國海證券Apr 29 00:00
Gibbel (688566): Core products help high performance growth, and the innovation pipeline is expected to continue to catalyze
德邦證券Mar 8 13:56
Gibbel (688566) 2023 performance report review: The performance is in line with expectations, and the two major varieties grew in volume as scheduled
東吳證券Feb 27 07:16
Gibbel (688566) First Coverage Report: Innovative pharmaceutical companies with specialty varieties in diverse disease fields can be expected in the future
國元證券Feb 5 00:00
Gibbel (688566): Marketing reforms continue to promote innovative platforms to drive long-term performance growth
華鑫證券Dec 27, 2023 00:00
Gibbel (688566) Science and Technology Innovation Board Company Dynamics Research: Marketing Changes Continue to Push Company Performance Into a Period of Rapid Growth
國海證券Nov 19, 2023 00:00
Gibel (688566): Sales reforms of small but beautiful innovative pharmaceutical companies stimulate vitality
東吳證券Jul 20, 2023 00:00
Gilbert (688566): Core products enable growth performance to be released at an accelerated pace
天風證券Dec 16, 2022 20:18
Gibel (688566): Science and Technology Innovation Board's purchase Strategy
國泰君安Apr 27, 2020 00:00
Gilbert (688566): The market share of oral whitening drugs reaches 80%, and the long-term development of the company still needs to be driven by R&D
安信證券Apr 23, 2020 00:00
Gibel (X19281): the integration of production and marketing and the coexistence of multiple products
海通證券Apr 9, 2020 00:00
Gibel (688566): the integration of "research, production and marketing" and the coexistence of multiple products
海通證券Apr 8, 2020 00:00
No Data
No Data